The discovery provides new evidence of a link between the body’s sleep cycle, governed by the hormone melatonin, and the disease.
The latest findings, published in Nature Genetics, could help to explain previous research that has shown night shift workers are prone to type 2 diabetes and heart disease.
Controlling diabetes has been one of the biggest concerns for medical practitioners and policy makers over the past few decades, as its toll on health and economy continues to rise alarmingly.
Scientists have found new evidence for a link between the body clock hormone melatonin and type 2 diabetes. The study found that people who carry rare genetic mutations in the receptor for melatonin have a much higher risk of type 2 diabetes.
In N.M., lifestyle intervention in six communities aims to turn around dangerous trend
Animas Corporation, a division of Johnson & Johnson that manufactures insulin pumps, has been reprimanded by the FDA for not reporting serious problems resulting from use of its equipment. The parent company was warned that it could face fines and more for selling faulty insulin pumps and failing to disclose serious injuries to diabetic patients who used the OneTouch Pink and 2020 insulin pumps. According to reports, J&J continued to sell the pumps even after the company knew that some had failed.
To the Editor: While it is not surprising that Susan Levin, who is with the animal rights group PCRM, advocates for a vegan diet, her statement that milk, meat and eggs cannot fit into a diabetic diet are not true.
Amylin Pharmaceuticals won approval Friday for its long-delayed diabetes drug Bydureon, a next-generation treatment that requires fewer injections than the company’s 7-year old diabetes medicine, Byetta.
About 1 in every 400 people suffers from type 1 diabetes , and that number continues to grow nationwide.
WASHINGTON (Reuters) – Amylin Pharmaceuticals Inc won U.S. approval on Friday for its Bydureon diabetes drug, a long-awaited victory for the company's most promising product. After two delays, the Food and Drug Administration approved once-weekly injectable Bydureon for treating adults with Type 2 diabetes, which is linked to poor diet and lack of exercise. Bydureon is a longer-acting form of …